

Factsheet



Greece

Men who have sex with men

Inject PrEP to protect?

The first Pan European study exploring the willingness to use long-acting injectable PrEP to prevent HIV.



What is the PROTECT Survey?


This online survey was conducted across Europe (Oct 2023 to March 2024) and sought to uncover who may benefit from the innovation that is long-acting injectable PrEP.

The European Commission (EC) has authorized Apretude ® (cabotegravir longacting [LA] injectable and tablets) for HIV prevention.

It is important for health services and policy makers to understand who may be interested in taking long-acting injectable PrEP so that resources can be most effectively allocated.


This factsheet reports on data from the PROTECT Survey collected in Greece from men who have sex with men N= 165.





Greece 165 👙

MIGRANT STATUS



RELATIONSHIP STATUS









CHEMSEX (in the past 6 months)

NUMBER OF SEXUAL PARTNERS (in the past 6 months)






Greece 165 👙

Example of campaign image



HIV TESTING FREQUENCY



ORAL Prep USE HISTORY & CURRENT Prep REGIMEN

■ Naive: 125 ■ Current: 24 ■ Former: 16





PROTECH



AWARENESS OF ORAL Prep

CURRENT PREP USERS – ACCESS TO ORAL PREP





Barriers to oral PrEP use

- 31% of the MSM said:
 - Oral PrEP was too costly (either the pills or the tests associated with PrEP use)
- 22% of the MSM said:
 - The procedure took too long to obtain oral PrEP when they needed it
- 59% of the MSM said:
 - Their healthcare provider did not offer oral PrEP to them
- 12% of the MSM said:
 - There was a waiting list at their healthcare provider for oral PrEP and the service was not available




Long-acting PrEP: interest and intention

65%

are interested in using LA-PrEP if it becomes available.

58%

intend to use LA-PrEP if it becomes available.



What LA-PrEP could mean to participants

This word cloud was generated from responses that participants provided to a question asking them what LA-PrEP could mean to them, if it were to become available.

Summary & Contact Information

SUMMARY

- Greek MSM are aware of PrEP and have taken up oral PrEP
- Barriers to starting PrEP still exist
- Interest and intention to use LA-PrEP among MSM in Greece is high
- LA-PrEP may provide an opportunity for greater HIV prevention in Greece

CONTACT INFORMATION

- Prof. Dr. Kai J. Jonas
 Email: kai.jonas@maastrichtuniversity.nl
- Dr. Johann Kolstee Email: johann.kolstee@maastrichtuniversity.nl
- Maastricht University postal address
 P.O. Box 616, 6200 MD Maastricht, The Netherlands